Hemophilia A Clinical Trial
Official title:
INdividualized ITI Based on Fviii(ATE) Protection by VWF (INITIATE)
The primary goal of the INITIATE trial is to compare the clinical outcome of individualized lot selection to random lot selection utilizing one plasma-derived von Willebrand factor (VWF)/coagulation factor (FVIII) complex concentrate for immune tolerance induction (ITI) in subjects with congenital Hemophilia A, FVIII activity ≤2%, and a historical high-titer inhibitor [≥5 Bethesda Unit (BU)].
Participants will be randomized on a one-to-one basis between one of two study arms,
individualized lot selection (alternative treatment arm) and random lot selection (standard
treatment arm, current US clinical practice in ITI). Study sites, participants, and
investigators will be blinded to the treatment status assigned.
Alternative treatment arm:
Half of the participants will be randomized to blinded individualized lot selection for ITI.
The target initial dose of FVIII for ITI is ~200 IU/kg/day intravenously. The suggested
maximum dose is 20,000 IU/day. Investigators may adjust the dose to a minimum dose of 150
units/kg if infusion volume is not feasible in patients without central venous access or in
patients with von Willebrand factor levels >250%. Splitting dose into two infusions per day
must be approved by the Steering Committee, and if approved, will be considered a protocol
deviation. Wilate® will be the VWF/FVIII complex concentrate (Octapharma USA, Inc., U.S.
License No. 1646) prescribed for ITI.
Individualized lot selection will be performed according to a modified Oxford method in a
central laboratory, by testing subject's plasma against 4-6 lots of Wilate® and selecting the
one with the highest residual FVIII (lowest Oxford titer) activity remaining after
incubation. The same lot will be used throughout the entire ITI course for each subject. If
the selected lot is depleted prior to the completion of ITI, a second individualized lot
selection will be performed using the original plasma sample provided at baseline.
Each Wilate® batch includes 1.6-1.8 million IU and is expected to last for about 3-57 months
depending on the weight of the subject and prescribed dose.
Standard treatment arm:
The other half of the participants will receive random lot selection for ITI. The dose and
concentrate used will be the same. Concentrate will be randomly selected from available
Wilate® lots. The same lot will be used throughout the entire ITI course for each subject. If
the random lot is depleted prior to the completion of ITI, a second lot will be randomly
selected. In both cases the random lot will be tested against subject's plasma to measure the
residual FVIII activity left after incubation but this result will not affect lot selection.
The primary hypothesis is that the time to negative inhibitor (<0.6 BU) will be shorter with
individualized lot selection compared to random lot selection and that this will impact
monthly break-through bleeding and reduce costs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03834727 -
Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
|
||
| Completed |
NCT03191799 -
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
|
Phase 3 | |
| Completed |
NCT01599819 -
BAX 855 Dose-Escalation Safety Study
|
Phase 1 | |
| Terminated |
NCT04541628 -
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A
|
Phase 1/Phase 2 | |
| Completed |
NCT02847637 -
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
|
Phase 3 | |
| Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
| Completed |
NCT04085458 -
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
|
Phase 4 | |
| Completed |
NCT04565236 -
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
|
Phase 4 | |
| Recruiting |
NCT05987449 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04621916 -
Preventing Inhibitor Recurrence Indefinitely
|
Phase 4 | |
| Not yet recruiting |
NCT02888223 -
Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
|
Phase 1 | |
| Completed |
NCT02528968 -
National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
|
N/A | |
| Completed |
NCT02225483 -
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
|
N/A | |
| Completed |
NCT02199717 -
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
|
N/A | |
| Completed |
NCT01217255 -
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
|
||
| Completed |
NCT00969319 -
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
|
N/A | |
| Terminated |
NCT00995046 -
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
|
N/A | |
| Completed |
NCT00868530 -
Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
|
Phase 3 | |
| Completed |
NCT00839202 -
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
|
N/A | |
| Completed |
NCT00629837 -
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
|
Phase 1 |